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Vaccination has been a major advance for health care, allowing eradication or reduction of incidence and mortality of
various infectious diseases. However, there are major pathogens, such as Human Immunodeficiency Virus (HIV) or the
causative agent of malaria, for which classical vaccination approaches have failed, therefore requiring new vaccination
strategies. The development of new vaccine strategies relies on the ability to identify the challenges posed by these
pathogens. Understanding the pathogenesis and correlates of protection for these diseases, our ability to accurately
direct immune responses and to vaccinate specific populations are such examples of these roadblocks. In this respect,
the use of a robust, cost-effective and predictive animal model that recapitulates features of both human infection and
vaccination is currently a much-needed tool. We discuss here the major limitations faced by modern vaccinology and
notably, the development of humanized mice for assessing the immune system, along with their potential as vaccine
models.
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One of the major advances in biomedical sciences resides
in vaccination, which has allowed the eradication or the
reduction of incidence and mortality of various infec-
tious diseases [1]. Smallpox eradication is one of the
best examples of vaccine efficacy.
Various types of vaccines have been developed and
applied in humans, and can be classified into two main
groups [2]. The first type of vaccine consists of live-
attenuated pathogens, which have been used successfully
against diseases such as smallpox, measles, polio and
yellow fever. These vaccines mimic natural infection, but
in a weakened non-pathogenic fashion. The second group
comprises a wide range of vaccines, including inactivated
toxins (diphtheria, tetanus), subunit preparations (hepatitis
B), carbohydrate cocktails (pneumococcus) and conjugate
vaccines (meningococcus, haemophilus influenza type B).
In contrast with live-attenuated vaccines that confer lifelong
memory, the second vaccination group usually requires ad-
juvants to enhance the induced immune response as well
as boosting strategies that maintain protective immunity.* Correspondence: behazine.combadiere@upmc.fr
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article, unless otherwise stated.Despite this major step ahead for global public health
and obvious benefits over the past century, vaccination
faces new challenges amidst a world of quickly evolving
pathogens. Specifically, classical vaccination approaches
for many pathogens have failed because the capacity to
generate fundamental knowledge regarding the patho-
genesis of these infectious diseases and the ability to
determine correlates of protection progress at a slower
pace. Further, the capacity to direct the types of immune
responses needed to confer protection through vaccin-
ation and to protect specific patient groups are affected
by the relevance and/or lack of adequate animal models.
Major infectious diseases for which no vaccine exists
For a wide range of pathogens, classical vaccination
approaches have achieved limited success. All of these
pathogens failed in the vaccine development path for
different reasons, which are addressed here.
1. High antigenic variability and immune evasion. Some
viruses such as Human Immunodeficiency Virus
(HIV) and Hepatitis C Virus (HCV) are characterized
by a high antigenic variability [3]. Their high mutation
rate allows them to evade immune responses by
modifying their target immunogens during the courseoM
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variability, several subtypes of these pathogens
co-exist, adding a layer of complexity to developing
broadly effective vaccines. Such immune evasion is
also a major problem for the development of a universal
Influenza vaccine, where annual updating of the viral
strains and targets in vaccines is required for
seasonal vaccination. Similarly, malaria represents a
complex hurdle for vaccination [4]. At each step of
the parasite’s complex life cycle, its morphology
and expressed antigens change. When combined
with allelic polymorphisms, these mutations allow
the parasite to evade the host immune response.
2. Disease enhancement. Dengue virus (DENV)
comprises 4 serotypes. After dengue infection,
neutralizing antibodies are generated, conferring life
long immunity against the infecting serotype. However,
cross-reactive antibodies against other non-infecting
serotypes are also generated and believed to increase
the severity of subsequent infections by other dengue
serotypes through antibody-dependent enhancement
[5]. One of the challenges facing the development of a
vaccine against DENV will be to induce a protective
antibody response against all four DENV serotypes. In
addition, the protective immune responses should be
durable and equally effective against all 4 dengue
serotypes to avoid an incomplete immune response,
which would further facilitate and enhance pathogenesis.
The recent results of the phase IIb Sanofi tetravalent
DENV vaccine highlighted this difficulty to induce
such equally protective immunity against the 4
serotypes [6]. This phenomenon was also observed
for respiratory syncytial virus (RSV) in a human
vaccination setting, where an incomplete immune
response after vaccination lead to vaccine-mediated
disease enhancement [7].
3. Time of the infection. RSV is one of the main causes
of respiratory infection in infants and efficient vaccine
against RSV represents an important yet unmet
medical need. A major issue with RSV is its timing of
infection, where infants in their first 6 months are at
highest risk of severe RSV disease, during a period
where the immune system is still immature [7].
Inducing effective immune responses that will
last in newborns is particularly challenging and may
require maternal immunization strategies with
mother-to-fetus transmission of protective antibodies.
4. Neglected tropical diseases. Viruses that are
circulating in tropical regions and cause hemorrhagic
fever, face a lack of interest in terms of an investment
in vaccine development, which does not necessarily
reflect an inability to elicit effective vaccine-induced
immune responses [8]. Indeed, for Junin virus (New
World Arenavirus), a live-attenuated vaccine is usedin Argentina, but this local vaccine has not been
approved for use in other countries. Similarly, for the
hemorrhagic fever with renal syndrome (HFRS)
caused by Old World Hantaviruses, a local vaccine
used in Korea and China have reduced the number of
HFRS cases since its implementation.
Deciphering correlates of protection
Whereas most successful vaccines have been developed
empirically, there is now a need for understanding the
pathogenesis of the infecting organism as well as the
disease-specific mechanisms of protective immunity and
immune evasion [2,9]. Most of the pathogens for which
effective vaccines exist are characterized by a primary
infection, which results in long-lasting resistance in the
surviving host. As a consequence, vaccines were devel-
oped to induce an immune response that mimics the
natural infection. Some pathogens that cause persistent
infection and also promote the development of cancer,
such as Hepatitis B and Papilloma viruses, can now be
prevented by vaccines that deliver virus-like particles.
The induction by vaccines of antibodies that confer
sterilizing protection against pathogens is usually defined
in vaccination as the correlates of protection. However,
for many diseases, we do not know which arms of the
immune system are responsible for conferring protection,
e.g. humoral versus cellular immunity, whether systemic
or mucosal immunity should be induced for sterilizing
protection. Parameters for the maintenance of protective
immunity over years also have yet to be elucidated. In
addition, for pathogens that do not induce robust resist-
ance after primary natural infection, it is unclear how to
confer sterilizing protection through vaccination. Systems
biology approaches are one of the favored strategies used
to decipher correlates of protection and predict vaccine
efficacy [10-12]. Systems biology is a combination of omic
technologies and computational tools that can be used to
obtain quantitative, qualitative and integrated analyses at
genomic, proteomic and cellular levels. This multipara-
metric approach helps define the innate signatures that
are induced early after infection and/or vaccination and
the subsequent adaptive response in humans, and as such
gives a global picture of the complex interaction between
the innate and adaptive arms of the immune system in
one individual at a certain time. This has already been
applied in the context of vaccinology studies against yel-
low fever and influenza [9].
Systems biology is a powerful tool to measure functional
signatures of T cell and B cell responses and may shift
the vaccinology dogma from correlates of protection as
a single parameter important for vaccine efficacy to
co-correlates of protection that combine multiple vari-
ables. In addition, not only the type of immune responses
needed to confer protection has to be deciphered
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correlates and co-correlates of protection have to be
defined in particular populations, including newborn,
infants, teenagers, adults, and the elderly; immunodeficient,
pregnant individuals and individuals with autoimmune dis-
ease. Moreover, antigen design for avoiding immune escape
is of importance, implying that balance between protective
and enhancing epitopes should be defined as well as the
mechanisms leading to the immunodominance of the
irrelevant epitopes. The fields of antigen design benefits
now from both reverse vaccinology and structural vaccinol-
ogy. Reverse vaccinology, based on the sequencing of the
genomes of pathogens, allows the in silico determination of
putative candidate vaccine antigens that were not found by
traditional methods. The recognized success of reverse vac-
cinology has been shown in obtaining an effective licensed
vaccine against meningococcus type B [13]. Structural vac-
cinology, based on information of the 3D structure of the
HIV envelope protein, is another key component that may
lead towards development of successful vaccines against
this virus or similarly, RSV [14,15].
How to shape the adaptive immune response
One of the main challenges in vaccination, knowing or
not correlates of protection, is to direct the immune sys-
tem toward responses that would confer protection. How
can potent antibody response be induced? How can Th1/
Th2/Th17 responses be balanced? How can mucosal im-
munity be induced? How can long-lasting memory cells
be induced?
For example, potent broadly neutralizing antibodies
against HIV proteins have been discovered but all of these
antibodies exhibit a particularly high level of hypersomatic
mutations [14], further complicating the task of generating
high affinity antibodies through vaccination. What is clear
is that innate immunity has a central role in programming
the adaptive immune response and consequently the pro-
tective one. Manipulating innate immunity at different
levels, as presented below, may thus impact the outcome
of protection by vaccination.
1) Adjuvants. Adjuvants have multiple facets. They
are used in non live-attenuated vaccines in order to
improve vaccine efficacy through increased antibodies
titers, CD4 T cell frequencies and/or enhanced
duration of the vaccine-induced immune responses
[16]. They may influence the isotype class switching
of antibodies and modulate the Th balance responses
(Th1/Th2/Th17). In terms of vaccine manufacturing
and large-scale production, use of adjuvants permits a
reduction in the antigen dose and the number of
doses required to provide protection. Few adjuvants
are currently used in licensed vaccines, which are
mainly added to enhance humoral immunity.However, a battery of new adjuvants is under
preclinical or clinical development and testing [16].
Identifying their precise mechanisms of action will
allow us to gain additional information about safety
and insight on how to shape the nature of immune
responses and duration of memory responses. In
addition, adjuvants may be combined in the same
vaccine formulation to maximize immunogenicity.
2) Vectors. Numerous vectors, replication competent
or incompetent, have been developed for vaccination
and characterized in preclinical models and clinical
trials [17,18]. They are able to induce cytotoxic T cell
responses in addition to antibody responses. Depending
on the infectious agent, one vector will be preferred to
another according to nature of immune responses
necessary for protection. However, one major
constraint to overcome is the potential pre-existing
immunity to some vectors, which may limit the
induction of the desired immune response against a
pathogen or even favor the replication of the pathogen
targeted by the vaccine vector. This has been observed
in the Merck STEP trial, where pre-existing immunity
against the vector, a recombinant Adenovirus type 5,
led to an increased incidence of HIV infection [19].
3) Route of vaccine administration. Intramuscular and
subcutaneous vaccination routes are the main
administration modes. However, antigen-presenting
cells (APC) are poorly represented in the muscle and
direct priming of T cells is impaired, as myocytes lack
expression of major histocompatibility complex
(MHC) class II and costimulatory molecules.
Consequently, adjuvants are necessary to enhance
APC activation and infiltration into and around the
intramuscular vaccination site. In addition, these
routes of immunization favor systemic immunity and
not mucosal tissues-associated immune responses.
This is of importance when the pathogen’s portal of
entry is the mucosal tissue.
New strategies are being developed for an alternative
mode of administration via mucosal tissues
(intranasal, oral, sublinguinal, intrarectal and
intravaginal) or cutaneous tissues (intradermal,
transcutaneous, percutaneous). We have a special
interest in the skin [20], since there is a higher density
of APC is present in the skin epidermis (Langerhans
cells) and dermis (dendritic cells). As APC are key
players in the induction and shaping of immune
responses, it is therefore tempting to use skin as a
target organ for vaccination. Cutaneous vaccine
immunization results in better antigen distribution
and sustained APC recruitment into draining lymph
nodes as compared to intramuscular administration.
Consequently, the features of the generated immune
response differ according to the administration route
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demonstrated that intradermal (ID) vaccination
induced immunogenicity similar to intramuscular
administration but with smaller antigenic doses [20].
However, at similar doses, a superior immunogenicity
was observed in the elderly population after
administration of an ID influenza vaccine [23].Specific population groups to vaccinate
Improved health care, with reduction of infant mortality
and decreased mortality in older age, leads to increased
life expectancy. This impacts vaccination campaigns, as
new target groups [24] such as the elderly population,
who are more prone to develop infectious diseases, should
be taken into account for new effective vaccination strat-
egies. Indeed, senescence of the immune system in the
elderly makes them more vulnerable to infections but also
renders them less responsive to vaccination. Specific strat-
egies to amplify the immune response, probably through
combination of adjuvants, may be required. This should
also take into account malnutrition and obesity, which may
change outcomes of vaccination. Furthermore, there is
more and more evidence of the impact of the microbiome
on immunity and consequently on responses to vaccines.
In other specific groups of patients such as immuno-
deficient people or pregnant women, live-attenuated
vaccines have to be avoided and switched toward the
second group of vaccines, comprising inactivated, sub-
unit, carbohydrates or conjugated vaccines. In addition,
for some pathogens such as RSV, where protection in
newborns is required shortly after birth, maternal immu-
nization strategies have to be developed to compensate
for the immaturity of the newborn immune system and
the difficulty to generate potent immune responses at
an early age.
Last, opponents of vaccination represent a growing group
in developed countries. For example, measles outbreaks are
more frequently observed; notably one case was docu-
mented in the USA that started from an unvaccinated child
in an undervaccinated population [25]. Strategies should be
undertaken to improve the social acceptability of vaccines.
Which animal models should be used for preclinical
vaccine development?
Preclinical vaccine development is limited by the lack of
adequate animal models. Indeed, whereas mice have
enormously contributed in understanding the immune
system ontogeny and function, these animal models
exhibit limitations for human vaccine development. Not-
ably, the dose of antigen and adjuvants delivered are not
representative of the corresponding human dose; the
route of antigen administration varies between mice and
humans as well as the expression of pattern recognition
receptors important for adjuvant efficacy. In addition, noprotection experiments can be performed with wild-type
pathogens when dealing with strictly human-tropic path-
ogens, such as HIV and DENV.
Non-human primates and in particular, chimpanzees
are another currently used preclinical model that have
been essential for the development of several vaccines,
including the hepatitis B one, but their elevated costs as
well as their restriction of utilization, which are often
due to ethical reasons, limits their large use. In addition,
HIV vaccination studies have shown limitations of such
models as different results were obtained in humans as
compared to the preclinical assessment in monkeys.
Indeed, SIV sequences are not as diverse as HIV sequences;
restriction factors such as TRIM5α or the (absence of the)
prevalence of some vaccine vectors in monkeys, such as
adenoviruses, may impact the outcomes of the vaccine
studies.
To overcome these limitations, efforts have been under-
taken to generate adequate predictive animal preclinical
models, easy to generate, cost-effective and allowing an
in vivo approach of the human immune system. Such
models would allow recapitulation of the characteristics of
infection by human pathogens and modeling vaccination
studies, consequently accelerating the transfer of vaccines
as well as new therapeutics from preclinical to clinical
stages.
The search for such models has intensified, resulting
in the construction of mice humanized for the immune
system (Human Immune System or HIS mice). These
models mainly arise from the xenotransplantation of
human hematopoietic cells and/or tissues, allowing the
long-term establishment of components of human immun-
ity in permissive immunodeficient mice. The generation of
new immunodeficient mouse strains – in particular NOD/
SCID/IL2Rγc
-/- (NSG/NOG) and BALB/c Rag-/-IL2Rγc
-/-
(BRG) - has led to considerable improvements for accept-
ance of human xenofgrafts [26-30]. A single injection of
human hematopoietic stem/progenitor cells allows the
development, maturation and long-term maintenance of a
multi-lineage human immune system, with all the major
human hematopoietic cell populations found in the recon-
stituted HIS mice [26-30].
Interestingly, these HIS mice can be infected by human-
specific lymphotropic pathogens targeting cells of the
immune system such as HIV and DENV [31]. HIS mice
are attractive tools for investigating pathogenesis of some
infectious diseases in a human setting, as well as new live-
attenuated HIV vaccines [32]. Several therapies have
already been preclinically tested in these animal models
and are mainly against HIV, such as microbicides or gene
therapy [33,34]. However, induction of strong humoral
and cellular immune responses in HIS mice still repre-
sents a major challenge. Human B and T cell responses
remain suboptimal in HIS mice after immunization and
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antigen-specific B cell repertoire at the clonal level after
commercial vaccine inoculation shows mainly an IgM
response with a restricted level of somatic hypermutations
[35]. Human T cells generated in NSG-HIS mice are edu-
cated in the context of a murine thymus, thus restricted
to mouse MHC molecules. After immunization of NSG-
HIS mice, proper CD4+ and CD8+ T-cell interactions with
human APC may therefore be impaired, which may in
turn limit B cell responses and the establishment of an
IgG antibody response [36]. HIS mice transgenic for
human MHC (HLA) class I and/or II molecules have
therefore been generated and exhibit improved T cell
functionality and improved IgG responses [37-39]. Never-
theless, further improvements are required to obtain
strong adaptive immune responses. One potential strategy
is to improve the density and/or functionality of human
APC that are underrepresented in HIS mice. Supplemen-
tation of HIS mice with human cytokines implicated in
the development and/or maturation of such cell com-
partments has demonstrated incremental optimization,
further moving humanized mice towards valuable preclin-
ical vaccine models [40,41]. Some vaccine strategies can
already be tested in HIS mice, such as targeted vaccine
delivery of Epstein-Barr virus nuclear antigen 1 to DC via
the DEC205 receptor [42] or DC immunotherapy [43].
Although HIS mice may require some optimization for
universal vaccine development and delivery, they already
offer several possibilities for obtaining crucial information
about the pathogenesis of some infections or the modula-
tion of innate immunity by adjuvants.
Conclusions
Despite major advances in health care made through
massive vaccine campaigns over the past century, the field
of vaccination faces new challenges. However, identifying
these challenges is already one big step. In addition, techno-
logical advances in vaccine discovery, reverse and structural
vaccinology, systems biology and immune monitoring,
together with the optimization of preclinical animal models
such as HIS mice, should help us bridge the gap to design-
ing a new range of vaccines against the causative agents of
current infectious diseases.
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